Intervention

DVS-233 SR

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting0

Common conditions3

Lead sponsors shown1

Clinical trials

8 shown

Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive DisorderNCT00242229 · 2004-10-01

Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive DisorderNCT00090649

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderNCT00073762

Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive DisorderNCT00087737

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderNCT00075257

Study Evaluating DVS-233 in Adult Outpatients With Major Depressive DisorderNCT00063206

Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive DisorderNCT00092911

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderNCT00072774

Common conditions

Major Depressive Disorder8 Depression1 Depressive Disorder1

Leading sponsors

Wyeth is now a wholly owned subsidiary of Pfizer8

Trial status mix

COMPLETED8

Phase mix

PHASE37

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.